|Articles|March 9, 2020
Novotech Wins Contract for Komipharm Coronavirus Covid-19 Trial in South Korea
Advertisement
Asia-Pacific biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus - Covid-19. Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
Using AI and Tokenized Data to Match Patients to Protocols
3
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
4
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
